Research programme: antibody-drug conjugates - Millennium Pharmaceuticals

Drug Profile

Research programme: antibody-drug conjugates - Millennium Pharmaceuticals

Alternative Names: ADCs - Millennium Pharmaceuticals; TAK-164

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium
  • Developer ImmunoGen; Takeda
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Oct 2017 Preclinical trials in Cancer in Japan (IV)
  • 24 Mar 2015 Early research in Cancer in Japan (unspecified route)
  • 23 Mar 2015 Millennium Pharmaceuticals in-licenses ADC technology from ImmunoGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top